Extended Half-Life Factor VIII Agents in Hemophilia A: Evaluating the Evidence and Integration Strategies

Extended half-life (EHL) rFVIII agents may alleviate some of the burdens associated with prophylactic treatment in hemophilia A. Their potential to decrease and better accommodate dosing regimens are a major step forward to optimize outcomes for these patients, and they have been shown in several clinical trials to be efficacious in controlling bleeding in both children and adults. Several EHL-rFVIII agents are approved for the treatment of hemophilia A and many more are in development. This educational webinar, led by expert Steven Pipe, MD, will review the latest clinical trial data about their efficacy and safety, as well as how to effectively incorporate these new agents in clinical practice.

Extended Half-Life Factor VIII Agents in Hemophilia A

Presenter: Steven Pipe, MD